February 24, 2021
Taiho Pharmaceutical said on February 22 that its cancer agent pimitespib hit the primary endpoint of progression-free survival (PFS) in a Japanese PIII study in patients with previously treated gastrointestinal stromal tumors (GISTs). The study, dubbed CHAPTER-GIST-301, was designed to...read more